Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Vascular Spasm

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preventing delirium after hip fracture surgery.

Anaesthesia·2021

Same author

Diabetes mellitus and the healing of periapical lesions in root filled teeth: a systematic review and meta-analysis.

International endodontic journal·2020

Same author

Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsets.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Same author

Can New Ultrasound Signs Help in Identifying Follicular Variant of Papillary Carcinoma of Thyroid? - A Pilot Study.

Ultrasound international open·2016

Same author

The innate immune system, toll-like receptors and dermal wound healing: A review.

Vascular pharmacology·2015

Same author

Primary squamous cell carcinoma of breast presenting as a cystic mass.

Journal of postgraduate medicine·2013

Search research articles

Related Experiment Video

Updated: Jul 1, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Endothelin--role in vascular disease.

D Abraham¹, M Dashwood

¹Department of Medicine, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK. d.abraham@medsch.ucl.ac.uk

Rheumatology (Oxford, England)

|September 17, 2008

Summary

Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in endothelial dysfunction and vascular disease. ET-1 receptor antagonists show promise in treating these conditions by modulating inflammatory pathways.

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Related Experiment Videos

Last Updated: Jul 1, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Area of Science:

Cardiovascular Biology
Molecular Medicine
Pathophysiology

Background:

Endothelin-1 (ET-1) is a potent vasoconstrictor discovered two decades ago.
ET-1 exerts its effects via ET(A) and ET(B) receptors found on various cell types, including endothelial cells, vascular smooth muscle cells, and fibroblasts.
ET-1 is increasingly recognized as a critical factor in endothelial dysfunction across cardiovascular diseases, autoimmune disorders, and connective tissue diseases (CTDs).

Purpose of the Study:

To review the current understanding of Endothelin (ETs) roles in vascular dysfunction and disease.
To highlight the specific involvement of ET-1 in connective tissue diseases (CTDs).
To explore the therapeutic potential of ET-1 receptor antagonists.

Main Methods:

Literature review of existing research on ET-1 and vascular disease.
Analysis of the mechanisms by which ET-1 contributes to endothelial dysfunction.
Examination of the role of ET-1 in connective tissue diseases (CTDs).

Main Results:

ET-1 is a key mediator in endothelial dysfunction, leading to inflammation and cell activation.
Beyond vasoconstriction, ET-1 influences vessel remodeling and interacts with growth factors and cytokines.
ET-1 plays a significant role in the pathophysiology of various cardiovascular, autoimmune, and connective tissue diseases (CTDs).

Conclusions:

ET-1 receptor antagonists may effectively mitigate vascular dysfunction and disease progression.
These antagonists can modulate vasoconstrictor pathways, inflammatory markers, and growth factor effects.
Targeting ET-1 pathways offers a promising therapeutic strategy for vascular and connective tissue diseases (CTDs).